REDWOOD CITY, Calif., May 27, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 to June 2, 2009, at the Orange County Convention Center in Orlando, FL.
